Literature DB >> 23734817

Arsenic speciation in the blood of arsenite-treated F344 rats.

Baowei Chen1, Xiufen Lu, Shengwen Shen, Lora L Arnold, Samuel M Cohen, X Chris Le.   

Abstract

Arsenic speciation in blood can improve understanding of the metabolism and toxicity of arsenic. In this study, arsenic species in the plasma and red blood cells (RBCs) of arsenite-treated female F344 rats were characterized using anion exchange and size exclusion chromatography separation with inductively coupled plasma mass spectrometry (ICPMS) and electrospray ionization tandem mass spectrometry (ESI MS/MS) detection. Arsenite (iAs(III)), arsenate (iAs(V)), monomethylarsonic acid (MMA(V)), dimethylarsinic acid (DMA(V)), trimethylarsine oxide (TMAO(V)), monomethylmonothioarsonic acid (MMMTA(V)), and dimethylmonothioarsinic acid (DMMTA(V)) were detected in the plasma, with DMA(V) being the predominant metabolite. Upon oxidative pretreatment with 5% hydrogen peroxide (H2O2), plasma proteins released bound arsenic in the form of DMA(V) as the major species and MMA(V) as the minor species. The ratio of protein-bound arsenic to total arsenic decreased with increasing dosage of iAs(III) administered to the rats, suggesting a possible saturation of the binding capacity of the plasma proteins. The proportion of the protein-bound arsenic in the plasma varied among rats. In the H2O2-treated lysates of red blood cells of rats, DMA(V) was consistently found as the predominant arsenic species, probably reflecting the preferential binding of dimethylarsinous acid (DMA(III)) to rat hemoglobin. iAs(V), MMA(V), and trimethylarsine oxide (TMAO(V)) were also detected in the hydrogen peroxide-treated lysates of red blood cells. Importantly, DMMTA(V) and MMMTA(V) have not been reported in rat blood, and the present finding of DMMTA(V) and MMMTA(V) in the rat plasma is toxicologically relevant because these pentavalent thioarsenicals are more toxic than their counterparts DMA(V) and MMA(V). Identifying novel thiolated arsenicals and determining protein-bound arsenicals in the blood provide useful insights into the metabolism and toxicity of arsenic in animals.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23734817     DOI: 10.1021/tx400123q

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  6 in total

1.  Preparation of DMMTAV and DMDTAV Using DMAV for Environmental Applications: Synthesis, Purification, and Confirmation.

Authors:  Hosub Lee; Youn-Tae Kim; Seulki Jeong; Hye-On Yoon
Journal:  J Vis Exp       Date:  2018-03-09       Impact factor: 1.355

2.  Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients.

Authors:  Meihua Guo; Jian Lv; Xiaotong Chen; Mengliang Wu; Qilei Zhao; Xin Hai
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

3.  Arsenic Induces Differential Neurotoxicity in Male, Female, and E2-Deficient Females: Comparative Effects on Hippocampal Neurons and Cognition in Adult Rats.

Authors:  Asmita Garg; Keerti Gupta; Rukmani Pandey; Pallavi Shukla; Kapil Mandrah; Somendu Roy; Naibedya Chattopadhyay; Sanghamitra Bandyopadhyay
Journal:  Mol Neurobiol       Date:  2022-02-17       Impact factor: 5.682

4.  Arsenic retention in erythrocytes and excessive erythrophagocytosis is related to low selenium status by impaired redox homeostasis.

Authors:  Zhihui Cai; Yutian Zhang; Weijie Zhang; Jinmin Ye; Qinjie Ling; Zhi Xing; Sichun Zhang; Peter R Hoffmann; Youbin Liu; Weidong Yang; Zhi Huang
Journal:  Redox Biol       Date:  2022-04-25       Impact factor: 10.787

5.  Gallic acid and MiADMSA reversed arsenic induced oxidative/nitrosative damage in rat red blood cells.

Authors:  Archna Panghal; Kshirod Bihari Sathua; S J S Flora
Journal:  Heliyon       Date:  2020-02-19

6.  Arsenic-Related Health Risk Assessment of Realgar-Containing NiuHuangJieDu Tablets in Healthy Volunteers Po Administration.

Authors:  Xiao Wu; Ruoning Yan; Rong Guan; Yi Du; Yuexin Liu; Shanhu Wu; Song Zhu; Min Song; Taijun Hang
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.